PD-L1 diagnostic test in non-small-cell lung cancer assessed in Swedish Örebro County Council

09

Dec 2019

In Sweden, the County Councils are grouped into six healthcare regions to facilitate cooperation and to maintain a high level of advanced medical care. One of them is Örebro County Council with its Centre for Assessment of Medical Technology (CAMTÖ). This center serving the whole of Örebro County Council commissioned to promote Evidence-Based Medicine and to act as an advisory body within the County Council in matters related to Health Technology Assessment. It initiates processes to distribute the conclusions of national or regional systematic literature reviews to healthcare through the Council for Medical Knowledge Management. It produces systematic literature reviews for decision making, for example, on introducing new methods, or disposal of existing methodology. It leads to the development of HTA cooperation in the healthcare region Uppsala-Örebro.

In November 2019, CAMTÖ has released an HTA report for PD-L1 positivity tested by McAb SP263 to guide immune checkpoint therapy in non-small-cell lung cancer that aimed to estimate what proportion of all tumors of a particular cancer form is suitable for immunotherapy, based on positive staining of various strength.

The literature search was performed with the following conclusions provided by CAMTÖ:

  • The patient groups examined were very different between each other, and the proportion that had a strong positive result varied greatly
  • No safe conclusions could be drawn, but the wide range of positivity rates implies the difficulties in the standardization of PD-L1 expression and the need for better predictive biomarkers
  • As immune inhibitors are very expensive, and also associated with severe side effects, it is necessary to keep up with how this area develops in the real-world setting

See the full information in Swedish here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

23

Mar 2022

In late January 2022, Swedish Medical Technologies Product (MTP) Council issued an updated version of recommendations regarding gene expression analysis for decision-making on the adjuvant breast cancer treatment, initially published in November 2021. The recommendation to the regions remains the same. The changes were only concerned with the clarification of some facts.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

17

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

Read more

16

Mar 2022

In February 2022, Swedish Medical Technologies Product (MTP) Council issued an updated recommendation on FreeStyle Libre for continuous glucose monitoring in type 2 diabetes (T2D). The initial recommendations were published by NT Council in 2018 and updated by MTP Council in 2020 to include FreeStyle Libre 2. In the 2022 update, MTP Council decreased the Hba1c limit from 70 to 60 mmol/mol and added a statement on lifestyle changes and treatment optimization with non-insulin antidiabetic drugs.

Read more